2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Baumann sheds light on the incidence, prognosis, and treatment of patients with Merkel cell carcinoma, ongoing clinical research, and strategies to raise awareness for this rare disease.
Welcome to a very special edition of OncLive On AirTM. I'm your host today, Jason Harris.
OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today's episode, we had the pleasure of speaking with Brian C. Baumann, MD, an assistant professor of radiation oncology and chief of Genitourinary Service in the Department of Radiation Oncology at Washington University School of Medicine in St. Louis.
In our exclusive interview, Baumann shed light on the incidence, prognosis, and treatment of patients with Merkel cell carcinoma, ongoing clinical research, and strategies to raise awareness for this rare disease.
Related Content: